Etienne Marc Grandjean, MD
Etienne has more than 25 years of experience both in University settings and in pharmaceutical and healthcare industries where he held leading positions in major and mid-sized companies:
- University Hospital of Geneva/Switzerland, where he served as a resident, then senior registrar for several years. He authored a number of publications on Drug Therapy and Clinical Toxicology.
- Zyma, a member of Ciba-Geigy Group (now part of Novartis), as a medical manager, development project leader, medical consultant for new business opportunities and head of research (drug discovery, including medicinal chemistry and pharmacology groups).
- Debiopharm, a Swiss drug development company, as Vice-President of development, he defined the profile and the development plan of the innovative drug, oxaliplatin, which later became an anticancer blockbuster. He also developed and supported peptidic compounds (vapreotide and triptoreline) in Endocrinology, Gynaecology and Oncology.
- Phidalsa, his own company, where he conducted about 30 Phase I and II Clinical Trials. He also performed clinical analyses based on meta-analysis, pharmaco-economics and epidemiological survey.
His consultancy activities are focused on non-clinical as well as clinical expert reports and new drug development, with emphasis on the non-clinical / clinical interface. He also provides safety advice on pharmaceutical and nutritional products for Switzerland, EU, and USA.
Etienne graduated as an MD from Geneva University/Switzerland. He obtained a board in Internal Medicine as well as in Clinical Pharmacology and Toxicology.